Legacy, Impact, and Achievements

Over two decades of research, the GDMCC made substantial contributions to the understanding and management of primary ciliary dyskinesia and primary immune deficiencies.

Clinical Contributions

  • Defined cardinal clinical features
  • Characterized the early origins and progression of lung disease 
  • Demonstrated the increased prevalence of heterotaxy and complex congenital heart disease
  • Defined rates of pulmonary function decline and patterns of structural airway damage
  • Conducted landmark longitudinal studies that established the natural history of the disease and revealed important differences in disease severity among genetic subtypes

Diagnostic and Genetic Advances

  • Validated nasal nitric oxide measurement as an important component of diagnostic testing 
  • Defined rate of pulmonary function decline in children
  • Defined prevalence of respiratory pathogens in childhood
  • Discovered many of the genes now known to cause primary ciliary dyskinesia
  • Established genotype-phenotype relationships that help explain variability in disease severity and progression
  • Improved diagnostic algorithms and expanded access to accurate diagnosis for individuals with suspected PCD

Advancing Clinical Trial Readiness

The GDMCC identified and evaluated key outcome measures for future therapeutic trials, including pulmonary function testing, imaging-based assessments, inflammatory biomarkers, nasal nitric oxide measurements, and pulmonary exacerbation rates.

These studies established critical infrastructure for future therapeutic development and contributed to the growing clinical trial ecosystem for PCD, including participation in the multinational CLEAN-PCD clinical trial (ClinicalTrials.gov: NCT02871778) and ongoing evaluation of novel clinical endpoints.

International Collaborations

Recognizing the importance of global partnerships in rare disease research, the GDMCC collaborated extensively with international investigators and patient communities. Key accomplishments include:

  • Partnership with the European PCD research consortium BESTCILIA.
  • Development and validation of the PCD Quality of Life (PCD-QOL) instruments.
  • Collaboration with international investigators to harmonize research approaches and facilitate global clinical trials.

Partnerships with Patient Advocacy Organizations

A hallmark of the GDMCC was its close partnership with patient advocacy groups and the broader rare disease community. Together, these efforts strengthened both research and patient care by:

  • Partnering with the PCD Foundation to improve awareness, education, and research participation.
    • Trained and certified PCD Clinical Care Centers across North America
    • Developed PCD Foundation Patient Registry
    • Launched the PCD Clinical Research Network
  • Partnering with the Immune Deficiency Foundation 
  • Building the infrastructure needed for future multicenter studies and therapeutic trials

A Lasting Legacy

The success of the GDMCC was made possible through the dedication of participating patients, families, investigators, clinical coordinators, and advocacy partners. Together, these efforts transformed the understanding of primary ciliary dyskinesia, improved diagnostic accuracy, strengthened clinical care networks, and accelerated the development of new therapies.

Although the Consortium's original funding period has concluded, its scientific discoveries, clinical resources, collaborative networks, and research infrastructure continue to shape the future of PCD research and care. The foundation established by the GDMCC has positioned the PCD community to pursue increasingly effective treatments and, ultimately, disease-modifying therapies for individuals living with this rare condition.